[HTML][HTML] Discovery strategies to maximize the clinical potential of T-cell engaging antibodies for the treatment of solid tumors
V Voynov, PJ Adam, AE Nixon, JM Scheer - Antibodies, 2020 - mdpi.com
T-cell Engaging bispecific antibodies (TcEs) that can re-direct cytotoxic T-cells to kill cancer
cells have been validated in clinical studies. To date, the clinical success with these agents …
cells have been validated in clinical studies. To date, the clinical success with these agents …
Targeted delivery of LXR agonist using a site-specific antibody–drug conjugate
Liver X receptor (LXR) agonists have been explored as potential treatments for
atherosclerosis and other diseases based on their ability to induce reverse cholesterol …
atherosclerosis and other diseases based on their ability to induce reverse cholesterol …
Metallothionein: a novel therapeutic target for treatment of inflammatory bowel disease
KE Dostie, AV Thees, MA Lynes - Current pharmaceutical …, 2018 - ingentaconnect.com
Inflammatory bowel disease (IBD) is a group of disorders characterized by chronic
inflammation within the gastrointestinal tract. It is a multifactorial disease associated with …
inflammation within the gastrointestinal tract. It is a multifactorial disease associated with …
Evaluation the potential of recombinant anti-CD3 nanobody on immunomodulatory function
S Moradi-Kalbolandi, A Sharifi-K, B Darvishi… - Molecular …, 2020 - Elsevier
T cells are the most predominant effector cells in immune-mediated elimination of cancer
and circumventing tumor progression. Among various approaches, T cells activation by …
and circumventing tumor progression. Among various approaches, T cells activation by …
[HTML][HTML] Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
GGW Sandker, J Middelburg, E Wilbrink… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background CD3 bispecific antibodies (CD3-bsAbs) require binding of both a tumor-
associated surface antigen and CD3 for their immunotherapeutic effect. Their efficacy is …
associated surface antigen and CD3 for their immunotherapeutic effect. Their efficacy is …
Imaging the pharmacokinetics and therapeutic availability of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
GGW Sandker, J Middelburg, E Wilbrink… - bioRxiv, 2023 - biorxiv.org
Background CD3 bispecific antibodies (CD3-bsAbs) require binding of both a tumor-
associated surface antigen and CD3 for their immunotherapeutic effect. Their efficacy is …
associated surface antigen and CD3 for their immunotherapeutic effect. Their efficacy is …
[HTML][HTML] Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus
T-cells are critically involved in the pathogenesis of systemic lupus erythematosus. Although
treatment with the anti-CD3 antibody has been reported to be effective in several …
treatment with the anti-CD3 antibody has been reported to be effective in several …
[HTML][HTML] Comparison of CD3e antibody and CD3e-sZAP immunotoxin treatment in mice identifies sZAP as the main driver of vascular leakage
Anti-CD3-epsilon (CD3e) monoclonal antibodies (mAbs) and CD3e immunotoxins (ITs) are
promising targeted therapy options for various T-cell disorders. Despite significant advances …
promising targeted therapy options for various T-cell disorders. Despite significant advances …
[PDF][PDF] Middelburg
GGW Sandker - … Kuenen,., arntzen, E., Hall, T. an …, 2023 - scholarlypublications …
Background CD3 bispecific antibodies (CD3-bsAbs) require binding of both a tumor-
associated surface antigen and CD3 for their immunotherapeutic effect. Their efficacy is …
associated surface antigen and CD3 for their immunotherapeutic effect. Their efficacy is …